Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 4, 2011 - Issue 6
Submit an article Journal homepage
69
Views
3
CrossRef citations to date
0
Altmetric
Drug Profile

Sipuleucel-T: a therapeutic cancer vaccine for the treatment of castration- or hormone-refractory prostate cancer

Marilyn N Bulloch University of Alabama-Tuscaloosa School of Medicine, Department of Internal Medicine, University Medical Center, Box 870326, Tuscaloosa, AL 35487, USA. [email protected]; Harrison School of Pharmacy, Auburn University, 1013 Hampton Fall Blvd, Apt 716, Brownsboro, AL 35741, USA; University of Alabama-Tuscaloosa School of Medicine, Department of Internal Medicine, University Medical Center, Box 870326, Tuscaloosa, AL 35487, USA. [email protected]; Harrison School of Pharmacy, Auburn University, 1013 Hampton Fall Blvd, Apt 716, Brownsboro, AL 35741, USA
,
Mohammed M Elayan Harrison School of Pharmacy, Auburn University, 1013 Hampton Fall Blvd, Apt 716, Brownsboro, AL 35741, USA; Harrison School of Pharmacy, Auburn University, 1013 Hampton Fall Blvd, Apt 716, Brownsboro, AL 35741, USA
&
Holly R Renfroe Harrison School of Pharmacy, Auburn University, 1013 Hampton Fall Blvd, Apt 716, Brownsboro, AL 35741, USA; Harrison School of Pharmacy, Auburn University, 1013 Hampton Fall Blvd, Apt 716, Brownsboro, AL 35741, USA
Pages 685-692 | Published online: 10 Jan 2014

References

  • American Cancer Society. Cancer Facts & Figures 2011. American Cancer Society, GA, USA (2011).
  • Heidenreich A, Bellmunt J, Bolla M et al. EAU Guidelines on prostate cancer: part 1: screening, diagnosis, and treatment of clinically localized disease. Eur. Urol.59, 61–71 (2011).
  • Hayward SW Cunha GR. The prostate: development and physiology. Radiol. Clin. North Am.38, 1–14 (2000).
  • Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N. Engl. J. Med.349, 366–381 (2003).
  • US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann. Intern. Med.149, 185–191 (2008).
  • Mohler J, Bahnson RR, Boston B et al. NCCN clinical practice guidelines in oncology: prostate cancer. J. Natl Compr. Canc. Netw.8, 162–200 (2010).
  • Kawachi MH, Bahnson RR, Barry M et al. NCCN clinical practice guidelines in oncology: prostate cancer early detection. J. Natl Compr. Canc. Netw.8, 240–262 (2010).
  • Heidenreich A, Bellmunt J, Bolla M et al. EAU Guidelines on prostate cancer: part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol.59, 572–583 (2011)
  • Small E, Fratesi P, Reese D et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol.18, 3894–3903 (2000).
  • Burch P, Breen J, Buckner J et al. Priming tissue-specific cellular immunity in a Phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res.6, 2175–2182 (2000).
  • Burch P, Croghan G, Gastineau D et al. Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate60, 197–204 (2004).
  • Small E, Schellhammer P, Higano C et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8051) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol.24, 3089–3094 (2006).
  • Kantoff P, Higano C, Shore N et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med.363, 411–422 (2010).
  • Kelly WK, Halabi S, Carducci MA et al. A randomized, double-blind, placebo-controlled Phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J. Clin. Oncol. 28, 18s(Suppl.), (2010) (Abstract LBA4511).
  • Schlom J, Arlene PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin. Cancer Res.13, 3776–3781 (2007).
  • Gulley JL, Madan RA, Arlen PM. Enhancing efficacy of therapeutic vaccinations by combinations with other modalities. Vaccine25S, B89–B96 (2007).
  • Gardasil® (Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Prescribing Information. Merck & Co., Inc., NJ, USA (2006).
  • Cervarix® (Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant) Prescribing Information. GlaxoSmithKline, NC, USA (2009).
  • Provenge (Sipuleucel-T) Prescribing Information. Dendreon Corp., WA, USA (2010).
  • Rini B, Weinberg V, Fong L et al. Combination immunotherapy with prostatic acid phasphatase pulsed antigen-presenting cells (Provenge) plus bevicizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer107, 67–74 (2006).
  • Beinart G, Rini B, Weinberg V et al. Antigen-presenting cells 8051 (Provenge®) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin. Prostate Cancer4, 55–60 (2005).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.